Menu
Menu
El GENOMiCS INSIGHTS Day Panama se llevará a cabo el próximo 30 de julio, en el restaurante Maito. Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica. Durante la jornada abordaremos temas clave como la transformación del diagnóstico genómico en Latinoamérica, las nuevas posibilidades clínicas de la biopsia líquida y experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™. Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región. A continuación, encontrará la agenda preliminar del evento.
What: SOPHiA GENETICS Exclusive Networking event
Where: Restaurante Maito
Date: 30 de julio
Time: 18h00-21h:00
18:00 – 18:30
Transformando el diagnóstico genómico en Latinoamérica con SOPHiA GENETICS.
Gabriela Acosta, Sales Executive LATAM, SOPHiA GENETICS
18:30 – 19:00
Expandiendo las posibilidades clínicas con las soluciones de biopsia líquida de SOPHiA GENETICS.
Luna Rodriguez, Subject Matter Expert LATAM, SOPHiA GENETICS
19:00 - 19:30
Biopsia líquida en la práctica clínica: experiencia real con la plataforma SOPHiA DDM™.
July Katherine Rodriguez Ariza, Directora científica, FICMAC
19:30 – 21:00
Dinner & Networking
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform.
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
We are thrilled to be back at 16th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
European Society for Medical Oncology (ESMO) Annual Meeting
SOPHiA GENETICS is excited to be part of the European Society For Medical Oncology (ESMO) Annual Meeting.
You will have the chance to chat with our experts at booth #8068 to discuss our solutions for BioPharma and to demo the universal SOPHiA DDM™ Platform.
Visit us at the Booth and find out how to:
✅ Transform your precision therapy journey with next-generation genomics solutions tailored to your unique requirements
✅ Optimize each stage of drug development with efficient end-to-end Clinical Trial Assay (CTA) and CDx development
✅ Rise above the noise and trust your results with decentralized and best-in-class NGS solutions
✅ Transform oncology data complexity into valuable insights with the power of AI
✅ Streamline your market access strategy by unveiling insights from real-world data
✅ Accelerate global testing adoption and enable sustainable patient access to precision therapies by harnessing the vast global SOPHiA DDM® network
Meet us there!
The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.
We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.
Key Discussion Points:
Learning Objectives:
July 1, 2026 | 1:00PM SGT
Traditional genomic analysis often requires sequential testing or a “one-size-fits-all” comprehensive genomic profiling (CGP) panel, leading to time-consuming workflows and increased costs. The new MSK-IMPACT® Flex powered with SOPHiA DDM™ solution offers an agile and modular approach to CGP, enabling labs to achieve flexible, cost-efficient, and scalable analysis of solid tumors.
Built on the expert-designed MSK-IMPACT® assay and combined with the adaptive analytics of the SOPHiA DDM™ Platform, this end-to-end solution delivers high-resolution profiling of complex biomarkers from DNA and RNA. Labs can tailor biomarker coverage to each sample, with the flexibility to add RNA and homologous recombination deficiency (HRD) analysis as needed.
By attending this session, you will:
Presenters:
Lina Li, Director, Product Management, Application, SOPHiA GENETICS
July 15, 2026 | 1:00 PM SGT
Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers. In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay.
Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology.
In this session you will:
SOPHiA GENETICS will be attending the International Society for Liquid Biopsy Annual Meeting (ISLB) in Madrid, Spain! We look forward to connecting with leaders and innovators to discuss the evolving role of data in shaping the future of healthcare. Meet us at Booth #21.
More information is coming soon!
The SOPHiA GENETICS team will be happy to see you join our co-hosted symposium with AstraZeneca on Monday, September 14th from 7h15 to 8h15 am.
“PTENtion to Detail: From Challenges to Enhanced PTEN Testing”
Speakers:
In this session, our speakers will delve into the landscape of PTEN alterations, highlighting its clinical significance in cancer, and discuss how advanced design and bioinformatics can enable more accurate and scalable testing, improving outcomes for patients with PTEN alterations.
SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. Find us at Booth #13 where our team of experts will be ready to discuss how SOPHiA DDM™ platform is helping laboratories and healthcare institutions advance data-driven oncology insights.
Come explore our partnership with the Memorial Sloan Kettering Cancer Center and our latest updates across the MSK solutions portfolio, including enhanced CNV detection with tumor purity and ploidy analysis in MSK-IMPACT® Flex, and new capabilities in MSK-ACCESS® including MSI and ctDNA fraction, now available on GEN2.
Also learn more about OncoKB™ which is now fully embedded in SOPHiA DDM™ oncology workflows, and what that means for somatic variant interpretation in practice.
Industry Symposium
Join our Industry Symposium to explore how combining MSK-IMPACT® Flex and MSK-ACCESS® on the SOPHiA DDM™ Platform unlocks deeper, more complete oncology insights. From real-world use cases to the latest liquid biopsy enhancements, this is a must-attend session for those looking to take their genomic profiling further.
Monday, 15 June | 2:30pm – 3:30pm | Ballroom
Integrating tissue and liquid biopsy for in-depth precision oncology insights
Dr. Maria De Bonis, Biologist and Health Manager, Fondazione Policlinico A. Gemelli IRCCS, Italy
Lina Li, Product Director of Solid Tumors, SOPHiA GENETICS
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.
Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don't miss this unique opportunity and reserve your spot now!
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.